A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.

Multidrug-resistant tuberculosis (MDR-TB), defined as TB caused by Mycobacterium tuberculosis strains resistant to isoniazid and rifampicin (the core anti-TB drugs currently in use), and extensively drug resistant tuberculosis (XDR-TB), defined as MDR-TB caused by strains resistant to at least one fluoroquinolone and one injectable second-line anti-TB drug in addition to isoniazid and rifampicin, has attracted interest at different levels (1-5).

[1]  G. Migliori,et al.  A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium , 2017, The Indian journal of medical research.

[2]  Francesco Castelli,et al.  Towards tuberculosis elimination: an action framework for low-incidence countries , 2015, European Respiratory Journal.

[3]  E. Pontali,et al.  Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis , 2015, Expert review of anti-infective therapy.

[4]  M. Salfinger,et al.  Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending , 2015, European Respiratory Journal.

[5]  M. Faccini,et al.  Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal , 2015, European Respiratory Journal.

[6]  F. Blasi,et al.  ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use , 2014, European Respiratory Journal.

[7]  M. Raviglione,et al.  Tuberculosis elimination: dream or reality? The case of Cyprus , 2014, European Respiratory Journal.

[8]  A. Sandgren,et al.  The European Union standards for tuberculosis care: do they need an update? , 2014, European Respiratory Journal.

[9]  A. Spanevello,et al.  Tuberculosis elimination: theory and practice in Europe , 2014, European Respiratory Journal.

[10]  P. Barnes,et al.  Future directions for the ERS: Presidential plans , 2013, European Respiratory Journal.

[11]  F. Blasi,et al.  ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases , 2013, European Respiratory Journal.

[12]  F. Blasi,et al.  Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium , 2013, European Respiratory Journal.

[13]  Marieke J. van der Werf,et al.  Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination , 2013, European Respiratory Journal.

[14]  T. Holtz,et al.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes , 2012, European Respiratory Journal.

[15]  Sonya S. Shin,et al.  Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis , 2012, European Respiratory Journal.

[16]  F. Blasi,et al.  Presenting the European Forum for TB Innovation: innovative thinking in progressing towards TB elimination in Europe , 2012, European Respiratory Journal.

[17]  Marcos Burgos,et al.  Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients , 2012, PLoS medicine.

[18]  M. Raviglione,et al.  Multidrug-resistant tuberculosis in Eastern Europe: still on the increase? , 2012, European Respiratory Journal.

[19]  K. Floyd,et al.  Scaling up interventions to achieve global tuberculosis control: progress and new developments , 2012, The Lancet.

[20]  V. Leimane,et al.  European Union Standards for Tuberculosis Care , 2012, European Respiratory Journal.

[21]  K. Kliiman,et al.  TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? , 2012, European Respiratory Journal.

[22]  K. Floyd,et al.  Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. , 2012, Bulletin of the World Health Organization.

[23]  A. Matteelli,et al.  Multidrug-resistant tuberculosis today. , 2012, Bulletin of the World Health Organization.

[24]  Alimuddin Zumla,et al.  Tackling the spread of drug-resistant tuberculosis in Europe , 2012, The Lancet.

[25]  A. Skrahina,et al.  Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk , 2011, European Respiratory Journal.

[26]  Alimuddin Zumla,et al.  Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC) , 2011, European Respiratory Journal.

[27]  L. Gabbasova,et al.  Global tuberculosis report (2014) , 2014 .